Brief: Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027
BRIEF-Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027 Oct 21 (Reuters) - Gen Ilac ve Saglik Urunleri Sanayi Ticaret A.S. GENIL.IS:
GEN ILAC - PARTICIPATES IN KAZAKHSTAN PHARMACEUTICAL PROCUREMENT TENDER VIA MED SERVICE PLUS
GEN ILAC - , 'INTRAFEN', MANUFACTURED AT GEN'S PRODUCTION FACILITY IN ANKARA, HAS WON IBUPROFEN TENDER IN KAZAKHSTAN
GEN ILAC - AGREEMENT EXPECTED TO CONTRIBUTE USD 1.19 MILLION TO GEN SALES IN 2027
GEN ILAC - FIRST DRUG DELIVERY SCHEDULED FOR NOVEMBER 2026, AGREEMENT COVERS 2027
Source text: ID:nIKA8VN81K
Further company coverage: GENIL.IS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Gen Ilac ve Saglik Urunleri Sanayi Ticaret
See all newsBrief: Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027
Brief: Gen Ilac Says It Participates In Kazakhstan Drug Procurement Tender Via Med Service Plus Authorized By Kazakhstan Representative Office Of Gen Ilac
Brief: Gen Ilac Says It Signs Supply And Distribution Agreement With Incyte On Oct 9
Brief: Gen Ilac Says It Completes Pharmaceutical Manufacturing Plant Investment In Azerbaijan
Brief: Gen Ilac Says It Is To Start Share Buyback Programme For Max 125 Mln Nominal Shares With Allocated Funds Of 1.5 Bln Lira